PHILADELPHIA, December 12, 2017: Morgan Lewis represented Repros Therapeutics, Inc., a development stage biopharmaceutical company, in its sale to Allergan plc. Under the terms of the merger agreement, a subsidiary of Allergan will commence a cash tender offer to purchase all of the outstanding shares of Repros common stock for $0.67 per share. Following the acceptance of the tendered shares, the merger will be consummated. The transaction is expected to close in the first quarter of 2018. Repros focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.
The Morgan Lewis team was led by partners Justin Chairman and Colby Smith. Partners Lou Beardell, Chris Betti, David Zelikoff, Paul Gordon and Kathy Sanzo aided in the transaction, along with of counsel Gail Griffin, senior attorneys Sally Liao and Carole Klein, and associates Doug Kingston, Daniel Hosein, Deping Chai, Donald Huddler, and Samuel Bryant.